Florida’s Attorney General launches “CHINA Prevention Unit” to protect Floridians’ data | London proposes accepting Chinese auditing standards to attract Shanghai Stock Connect issuers | PE firms struggle to exit their Chinese PE investments amid lower valuations
Jianwei (Jerry) Fang, Haoyi Sun, Chen (Cissy) Chen and Chenai Kuang of Zhong Lun Law Firm examine and discuss the key legislative reforms and judicial developments in China’s civil and commercial dispute resolution landscape which took place in 2025
Xiucheng (Cecilia) Zhang of Sunsea Law Group P.C. examines proposed changes to China’s key law on enterprise bankruptcy which will dramatically change the insolvency landscape, and have notable repercussions for offshore debtors
Jianwei (Jerry) Fang, Rui Yang, Songyang Wang and Chen (Cissy) Chen of Zhong Lun Law Firm explain a new transparency drive requiring companies, partnerships, and foreign companies’ branch offices in Mainland China to file beneficial ownership information with local authorities. The authors outline the critical aspects of the new rules, including the scope of entities subject to the filing, the identification of beneficial owners, key deadlines, and the importance of timely compliance
Shanghai issues typical cases on patient and consumer data leakages. | Some rare earth shipments accelerated following China’s issuance of general export licenses. | China’s securities regulator strengthens rules to combat financial fraud in listed companies
Venture capital firm's Chinese investment to be reviewed by U.S. Treasury; Small-scale M&A on the rise despite trade tensions, sluggish growth; and U.S. Congressmen urge delisting of 25 Chinese groups from U.S. exchanges.
CSRC exempts state secrets from company disclosure / CLP Reference: 2300/25.04.07 ; Promulgated: 2025-04-07 ; Effective: 2025-07-01
Jianwei (Jerry) Fang, Xiaoyu (Arthur) Jin and Haoyi Sun of Zhong Lun Law Firm discuss the reasons behind, and the implications of, Illumina’s inclusion in China’s Unreliable Entity List, as well as compliance recommendations for multinational corporations
Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
Jianwei (Jerry) Fang, Chuchen (Julie) Hou and Jiaying (Kate) Jiang of Zhong Lun Law Firm discuss last year’s most significant legislative and judicial developments in civil and commercial dispute resolution in China
